Phase 2 N=39 Electroconvulsive Therapy in Clozapine Refractory Schizophrenia
Schizophrenia
Primary: Response Rates in the ECT Plus Clozapine Group vs the Pharmacotherapy Group. — 50; 0 Percentage of responders
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=267 Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Hypertension
Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at Endpoint (Phase 1) — -5.54; -5.42; -9.03 millimeter(s) of mercury (mmHg)
Phase 2 N=69 Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema)
Dermatitis, Atopic
Primary: Percent Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 4 — -81.7; -29.9 percent change — p=<0.0001
Phase 2 N=547 Safety Study of Apixaban in Recent Acute Coronary Syndrome
Acute Coronary Syndrome (ACS)
Primary: Event Rate of Composite of Adjudicated Major Bleeding and Clinically Relevant Non-Major Bleeding During the Treatment Period- Treated Participants With Placebo or…
Phase 2 N=153 A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship Between Skin Toxicity and Survival
Pancreatic Cancer
Primary: Number of Participants Who Died During the Study — 102; 27 participants
Phase 3 N=268 Investigation of the Superiority Effect of Desmopressin to Placebo in Terms of Night Voids Reduction in Nocturia Adult Female Patients
Nocturia
Primary: Change From Baseline in Mean Number of Nocturnal Voids Averaged Over a 3-Month Period — -1; -1.21; -1.25; -1.47 nocturnal voids — p=0.0280
N/A N=364 An Integrated Care Model for Improving Hepatitis C Virus Patient Outcomes
Hepatitis C
Primary: Sustained Virologic Response Rates — 29; 14 participants
Phase 2 N=498 Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients
Heart Failure With Reduced Ejection Fraction
Primary: Number of Participants Experiencing Hypotension, Renal Dysfunction, Hyperkalemia and Angioedema and by Renin-Angiotensin-Aldosterone System (RAAS) Stratum (High vs. Low)…
Phase 3 N=241 Improving Function in Age-Related Macular Degeneration
Age-Related Macular Degeneration
Primary: Targeted Vision Function (TVF) — 2.18; 2.14 units on a scale — p=.47
Phase 3 N=395 Investigation of the Superiority Effect of Orally Disintegrating Desmopressin Tablets to Placebo in Terms of Night Voids Reduction in Nocturia Adult Male Patients
Nocturia
Primary: Change From Baseline in Mean Number of Nocturnal Voids Averaged Over a 3-Month Period — -1.06; -0.973; -0.591; -1.4 nocturnal voids — p=<0.0001
Phase 3 N=374 A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus
Diabetes Mellitus
Primary: Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE) — 97; 47; 58; 49 Participants
Phase 2 N=210 Pioglitazone in Early Parkinson's Disease
Parkinson's Disease
Primary: Change in Total Unified Parkinson's Disease Rating Scale (UPDRS) Score From Baseline to 44 Weeks — 4.42; 5.13; 6.25 units on a scale
N/A N=29 Environmental Intervention to Reduce Allergens in Urban Schools and Childhood Asthma
Asthma
Primary: Asthma Symptoms — 1.5; 2.9; 1; 0.4 Days
Phase 4 N=178 A Comparison of Two Therapeutic Strategies for the Treatment of Aspirin-associated Peptic Ulcers
Peptic Ulcer
Primary: Number of Participants in Whom Peptic Ulcer Was Healed — 66; 66 participants
N/A N=150 A Comparison of Two Color Contact Lenses in Habitual Clear Contact Lens Wearers
Myopia
Primary: Lens Comfort Likert Response at Day 30 — 81.4 percentage of subjects